Jeffrey Rosen, M.D., D.A.B.F.M., F.A.A.F.P.
Dr. Jeffrey Rosen, Medical Director of Clinical Research of South Florida, has 34 years of clinical research experience in many therapeutic areas. He is a founding member of the Alliance for Multispecialty Research and is on the Leadership Counsel for the Society for Clinical Research Sites. Dr. Rosen has been a speaker at many research conferences, including the World Vaccine Conference, Partnerships in Clinical Trials and SCOPE Summit for Clinical Research Executives. He is also a speaker for several pharmaceutical companies. Dr. Rosen’s articles have been published in various medical journals. Dr. Rosen practices family medicine with PrimeCare of Coral Gables, a private group practice adjacent to his research site. Dr. Rosen is an associate clinical professor of Family Medicine at the University of Miami Miller School of Medicine and at the Florida International University Herbert Wertheim College of Medicine. He is a graduate of SUNY Downstate Medical Center, a Diplomat of the American Board of Family Medicine and a Fellow of the American Academy of Family Physicians. Dr. Jeffrey Rosen has served as the Principal Investigator for over 500 clinical trials and is also a founding member of AMR.
Clinical Research of South Florida
Clinical Research of South Florida was founded in 1975 and has conducted more than 800 clinical trials in many therapeutic areas. CRSF has six full-time clinical research coordinators with three coordinator assistants/recruiters with over 70 years of combined research experience. CRSF has the ability to perform procedurally difficult trials and can successfully recruit special populations. Major indication of research specialties include: Type II Diabetes Mellitus, Vaccines, Men’s and Women’s Health, and Hyperlipidemia. CRSF has the ability to perform in-office surgery, subcutaneous device implantation, pap smears, endometrial biopsies, joint aspirations/injections, urine flow meter, onsite skin biopsies and cryosurgery. In addition, CRSF has overnight capabilities at their site and an affiliation with a local phase I unit.